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Background: Adiponectin is a protein synthesized by adipocytes that exerts enhanced wellbeing among healthy adults, yet high adiponectin 
correlates with poor prognosis in patients with heart failure (HF). Cardiac cachexia in HF patients is thought to mediate adiponectin resistance and 
related detrimental effects. Since cachexia is not common, we studied adiponectin in HF patients with average physiques to better understand its 
effects among a typical HF population.
methods: Male systolic HF patients (LVEF ≤40%) aged ≥50 years were compared to age-matched controls. Adiponectin was assessed serologically. 
Body composition was assessed using dual-energy X-ray absorptiometry (DXA).
results: Sixty-four adults (30 HF and 34 controls) were studied. Table 1a shows that there were no significant differences between the two groups 
in age, weight, height, or BMI. DXA data showed that total fat and total lean body mass were similar between the groups. Table 1b shows serum 
indices of carbohydrate metabolism in HF patients and controls. Adiponectin and brain natriuretic peptide (NT-proBNP) levels were significantly 
increased in the HF patients vs. controls.
conclusion: While previous studies have attributed adiponectin resistance to disease-related cachexia, we show that adiponectin levels are 
similarly elevated in HF patients with normal physiques. Future studies are needed to further delineate adiponectin resistance in non-cachectic HF 
patients, and its potential use as a marker of HF prognosis.
 
